'Daedalus dilemma' of the immune system

The molecule IL-1β plays a key role in the balanced defense against bacteria

Which are the molecules that ensure a balanced immune response? The research of Pavel Kovarik and his team at the Max F. Perutz Laboratories of the University of Vienna addresses this question. "For our experiments we simulated infections with group A Streptococci, which are best known as the common cause of tonsillitis. However, in some cases, they can also cause serious invasive infections. The related disease -- toxic shock syndrome and necrotizing fasciitis -- can be fatal," explains PhD student and first author of the study Virginia Castiglia. As part of a project funded by the Austrian Science Fund FWF project, the young scientist examined what happens at the molecular level in invasive streptococcal infection. Her results show that the molecule IL-1β play a key role in the defense against streptococci: if there is too little, the bacteria gain the upper hand followed by blood poisoning, if there is too much, the result is excessive inflammation. Both can be lethal.

Tipping the scales: type I interferons

But how is the amount of IL-1β regulated? "We could show that type I interferons (IFN-I) are key," says study lead Pavel Kovarik: "We have known for a long time that IFN-I helps in the fight against viruses, but their role in the defense against bacteria was far less clear. For the first time, we could now show in our model system that they also play an important role in bacterial infections too by reducing the amount of IL-1β and so preventing excessive inflammation."

New therapies to treat invasive streptococcal disease

These results should now prompt medical research as it is important to understand, besides the model system, how the amount of IL-1 β is balanced in patients and how it is related to the severity of the infection. Virginia Castiglia explains: "In our model we have shown that if IFN-I effects are reduced, treatment with inhibitors of IL-1β synthesis have positive effects and balance is restored. Once we understand the relationship between IFN-I and IL-1β in humans, we can test these and similar therapies." Until now, serious invasive streptococcal infection can only be treated symptomatically. Antibiotics only help in the early stages and anti-inflammatory agents show little effect. Often the only way is the generous removal of the inflamed tissue. So there is still a lot to do for Pavel Kovarik and his team. Virginia Castiglia also continues to address questions related to infection biology. Since mid-February, she is a Postdoc at the Institut Pasteur in Paris, funded by a prestigious Marie Curie grant from the European Union.